The NHS has provided health and care, free at the point of delivery, for more than 75 years. It is rightly held as a national ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

Dostarlimab (Jemperli) with platinum-based chemotherapy is available on the NHS. It is a possible treatment for when systemic treatment is suitable in adults with primary endometrial cancer that has ...

The evaluation committee considered evidence submitted by GSK, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

Dostarlimab (Jemperli, GlaxoSmithKline) is indicated 'in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and ...

Marstacimab is the first under the skin (subcutaneous) injection for severe haemophilia B and today’s decision comes just weeks after the treatment received its UK licence. Given as a once-weekly ...

Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing IPG621 31 July 2018 31 July 2018 Low-intensity pulsed ultrasound to promote healing of fresh fractures ...